Get the Stockscreener App
5.14
4.47%
0.22
After Hours:
5.11
-0.03
-0.58%
Nuvation Bio Inc stock is traded at $5.14, with a volume of 4.18M.
It is up +4.47% in the last 24 hours and up +18.98% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.92
Open:
$5.04
24h Volume:
4.18M
Relative Volume:
1.04
Market Cap:
$1.79B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-12.00
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
+7.08%
1M Performance:
+18.98%
6M Performance:
-39.60%
1Y Performance:
+197.11%
1-Day Range:
$4.87
$5.165
1-Week Range:
$4.45
$5.64
52-Week Range:
$1.57
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.14 | 1.71B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Why Is Nuvation Bio Back On Penny Stock Watchlists? - Kalkine Media
Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level (NYSE:NUVB) - Seeking Alpha
Nuvation Bio director Robert Mashal buys $118,250 in stock - Investing.com
Nuvation Bio (NUVB) director’s trust buys 25,000 Class A shares - Stock Titan
Nuvation Bio stock reiterated at Market Outperform by Citizens - Investing.com India
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Spotlight On Promising Penny Stocks For June 2026 - simplywall.st
RBC Capital reiterates Nuvation Bio stock rating on ROS1 space value By Investing.com - Investing.com Australia
RBC Capital reiterates Nuvation Bio stock rating on ROS1 space value - Investing.com Nigeria
Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB) Presents Outcomes from TRUST-II Study - Insider Monkey
Nuvation Bio’s cancer drug sNDA accepted by FDA for review - Investing.com
5 Best Penny Stocks with Huge Upside Potential - Insider Monkey
RBC Capital raises Nuvation Bio stock price target on glioma potential - Investing.com
NUVB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
NUVB Q1 2026 Earnings: Modest EPS Beat Amid Continued Clinical ProgressEarnings Stability Report - newsline.com
Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Best Stocks Under $15 to Buy Right Now for High Growth Potential - Analytics Insight
Nuvation Bio execs to speak at Jefferies Healthcare Conference on June 3, 2026 - Pluang
Nuvation Bio to Present at the Jefferies Global Healthcare Conference - Investing News Network
Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay - Stock Titan
Nuvation Bio (NUVB) Reveals Promising Data from TRUST-II Study - GuruFocus
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting - Investing News Network
Nuvation Bio presents quality of life data for IBTROZI at ASCO - Investing.com Nigeria
Nuvation Bio presents quality of life data for IBTROZI at ASCO By Investing.com - Investing.com South Africa
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting - PR Newswire
Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing - Stock Titan
Nuvation Bio (NASDAQ: NUVB) awards 123,397 stock options to director - Stock Titan
Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79 - Stock Titan
Director at Nuvation Bio (NASDAQ: NUVB) awarded 123,397 stock options - Stock Titan
Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036 - Stock Titan
NUVB: IBTROZI's rapid first-line growth and robust pipeline drive strong outlook and financial stability - TradingView
NUVB: IBTROZI's strong first-line growth and pipeline progress drive optimism for future expansion - TradingView
Truist Securities Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - MSN
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug - MSN
NUVB: All proposals passed, including director elections and auditor ratification, with strong quorum - TradingView
Nuvation bid to expand Ibtrozi label undergoes FDA review - MSN
NUVB: IBTROZI and safusidenib drive growth, with new DDC platform updates and strong financial runway - TradingView
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
Are options traders betting on a big move in Nuvation Bio stock? - MSN
Earnings call transcript: Nuvation Bio Q1 2026 revenue beats forecast, stock jumps - Investing.com Nigeria
David Abrams's Nuvation Bio Inc(NUVB) Holding History - GuruFocus
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth - MSN
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment - Moomoo
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of Ibtrozi For Ros1-Positive Non-Small Cell Lung Cancer - TradingView
Nuvation Bio partners with Thermo Fisher for US drug manufacturing By Investing.com - Investing.com South Africa
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):